MedTrace Logo

Neural Network-based Treatment Decision Support Tool in Patients With Refractory Solid Organ Malignancies

NCT05719428 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-07-25

No results posted yet for this study

Summary

DRUID is a treatment decision support tool combining predictive models and public databases related to multi-gene markers, drug response screens, gene essentiality and clinical status of drugs to provide drug recommendations personalized based on an input genomic profile. We hypothesize that DRUID analysis of patients' somatic mutational profile from NGS diagnostic platform can be used as a treatment decision support tool in patients with refractory cancer without targetable mutations.

Conditions

  • Solid Organ Malignancies

Interventions

OTHER

DRUID AI Program

Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.

Sponsors & Collaborators

  • School of Computing, National University of Singapore

    collaborator UNKNOWN

  • National University of Singapore

    collaborator OTHER

  • National University Hospital, Singapore

    lead OTHER

Principal Investigators

  • Robert John Walsh · National University Hospital, Singapore

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05719428 on ClinicalTrials.gov